HbA1c indicates hemoglobin A1c.
High clinical complexity was defined as a composite measure of age of 75 years or older or high comorbidity burden defined by presence of end-stage renal disease, dementia, or 3 or more chronic conditions (myocardial infarction, congestive heart failure, pulmonary disease, non–end-stage chronic renal disease, or cancer). Intensive treatment was defined as a composite measure of intensive baseline regimen (use of greater number of medications than recommended for a given index hemoglobin A1c [HbA1c] level) and treatment intensification despite a low index HbA1c result. Risk-adjusted probabilities are adjusted for patient sex, race, household income, residency region, index HbA1c year, and specialty of treating health care professional. Error bars indicate 95% CIs.
High clinical complexity was defined as a composite measure of age of 75 years or older or high comorbidity burden defined by the presence of end-stage renal disease, dementia, or 3 or more chronic conditions (myocardial infarction, congestive heart failure, pulmonary disease, non–end-stage chronic renal disease, or cancer). Intensive treatment was defined as a composite measure of intensive baseline regimen (use of greater number of medications than recommended for a given index HbA1c level) and treatment intensification despite a low index HbA1c result. Error bars indicate 95% CIs.
eMethods 1. OptumLabs Data Warehouse
eMethods 2. Codes Used to Identify Patients With Diabetes Mellitus, Severe Hyperglycemia and Severe Hypoglycemia, and HbA1c Tests
eMethods 3. Criteria for Clinical Complexity
eMethods 4. Sensitivity Analysis Excluding Sulfonylurea and Glinide Use
eMethods 5. Sensitivity Analysis Excluding Metformin Use as Criterion for Intensive Treatment
eFigure 1. Study Design
eFigure 2. Risk Factors for Intensive Treatment
eTable 1. Glucose-Lowering Medications
eTable 2. Observed and Risk-Adjusted Probabilities of Intensive Treatment and Incident Severe Hypoglycemia Among Low- and High-Complexity Patients Excluding Sulfonylurea- and Glinide-Treated Patients
eTable 3. Risk-Adjusted Probability of Severe Hypoglycemia as a Function of Clinical Complexity and Treatment Intensity Excluding Sulfonylurea- and Glinide-Treated Patients
eTable 4. Observed and Risk-Adjusted Probabilities of Intensive Treatment and Incident Severe Hypoglycemia Among Low- and High-Complexity Patients Excluding Metformin as a Criterion for Intensive Treatment
eTable 5. Risk-Adjusted Probability of Severe Hypoglycemia as a Function of Clinical Complexity and Treatment Intensity Excluding Metformin as Criterion for Intensive Treatment
eResults 1. Sensitivity Analysis Excluding Sulfonylurea and Glinide Use
eResults 2. Sensitivity Analysis Excluding Metformin Use as Criterion for Intensive Treatment
Customize your JAMA Network experience by selecting one or more topics from the list below.
McCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND. Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Intern Med. 2016;176(7):969–978. doi:10.1001/jamainternmed.2016.2275
Intensive glucose-lowering treatment among patients with non–insulin-requiring type 2 diabetes may increase the risk of hypoglycemia.
To estimate the prevalence of intensive treatment and the association between intensive treatment, clinical complexity, and incidence of severe hypoglycemia among adults with type 2 diabetes who are not using insulin.
Design, Setting, and Participants
Retrospective analysis of administrative, pharmacy, and laboratory data from the OptumLabs Data Warehouse from January 1, 2001, through December 31, 2013. The study included nonpregnant adults 18 years or older with type 2 diabetes who achieved and maintained a hemoglobin A1c (HbA1c) level less than 7.0% without use of insulin and had no episodes of severe hypoglycemia or hyperglycemia in the prior 12 months.
Main Outcomes and Measures
Risk-adjusted probability of intensive treatment and incident severe hypoglycemia, stratified by patient clinical complexity. Intensive treatment was defined as use of more glucose-lowering medications than recommended by practice guidelines at specific index HbA1c levels. Severe hypoglycemia was ascertained by ambulatory, emergency department, and hospital claims for hypoglycemia during the 2 years after the index HbA1c test. Patients were categorized as having high vs low clinical complexity if they were 75 years or older, had dementia or end-stage renal disease, or had 3 or more serious chronic conditions.
Of 31 542 eligible patients (median age, 58 years; interquartile range, 51-65 years; 15 483 women [49.1%]; 18 188 white [57.7%]), 3910 (12.4%) had clinical complexity. The risk-adjusted probability of intensive treatment was 25.7% (95% CI, 25.1%-26.2%) in patients with low clinical complexity and 20.8% (95% CI, 19.4%-22.2%) in patients with high clinical complexity. In patients with low clinical complexity, the risk-adjusted probability of severe hypoglycemia during the subsequent 2 years was 1.02% (95% CI, 0.87%-1.17%) with standard treatment and 1.30% (95% CI, 0.98%-1.62%) with intensive treatment (absolute difference, 0.28%; 95% CI, −0.10% to 0.66%). In patients with high clinical complexity, intensive treatment significantly increased the risk-adjusted probability of severe hypoglycemia from 1.74% (95% CI, 1.28%-2.20%) with standard treatment to 3.04% (95% CI, 1.91%-4.18%) with intensive treatment (absolute difference, 1.30%; 95% CI, 0.10%-2.50%).
Conclusions and Relevance
More than 20% of patients with type 2 diabetes received intensive treatment that may be unnecessary. Among patients with high clinical complexity, intensive treatment nearly doubles the risk of severe hypoglycemia.
Clinical guidelines recommend targeting a hemoglobin A1c (HbA1c) level less than 7.0% for most nonpregnant adults with type 2 diabetes. Although tight glycemic control may have benefits for some patients with type 2 diabetes, achieving an HbA1c level of less than 7.0% in others may result in higher burden of treatment, higher cost, more adverse drug reactions, and increased risk of hypoglycemia.1-4 In particular, patients with complex health problems, limited life expectancy, and advanced age are unlikely to benefit from tight glycemic control and are more likely to be harmed by it compared with younger, healthier patients.5-12 Accordingly, the American Geriatrics Society (AGS) Choosing Wisely initiative advises against use of medications other than metformin to achieve an HbA1c level of less than 7.5% in most older adults with diabetes because of the risk of hypoglycemia and other harms, including mortality.13 Instead, the AGS recommends targeting an HbA1c level of 7.0% to 7.5% in healthy older adults with a long life expectancy, 7.5% to 8.0% in adults with moderate comorbidity and a life expectancy of less than 10 years, and 8.0% to 9.0% in patients with multiple comorbidities and a shorter life expectancy.13 These recommendations are consistent with, although not explicitly stated by, other clinical guidelines that promote individualized evidence-based diabetes care.14-21 However, despite these recommendations, intensive control remains prevalent among older, sicker patients with diabetes.22,23
Prior studies22,23 have not assessed the prevalence or effect of intensive treatment among younger patients or those using medications other than insulin or sulfonylureas. Moreover, relatively little is known about treatment practices and outcomes among patients once they achieve recommended tight glycemic targets. A recent study24 from the US Veterans Health Administration revealed that treatment is rarely deintensified among patients with very low (<6.0%) and moderately low (6.0%-6.4%) HbA1c levels. In addition to the lack of deintensification, patients with controlled diabetes (HbA1c level <7.0%) are also at risk for treatment intensification and potentially unnecessary polypharmacy. High rates of redundant HbA1c testing were previously found among low-risk patients with stable, controlled, non–insulin-requiring type 2 diabetes.25 Such overtesting was associated with treatment intensification, although overall treatment intensity could not be ascertained. Moreover, that study25 focused specifically on low-risk patients rather than patients with clinical complexity. The goals of this study were therefore to quantify the prevalence of intensive treatment specifically among patients with clinically complex controlled type 2 diabetes and to estimate the association between intensive treatment, clinical complexity, and incidence of severe hypoglycemia.
Question What is the association between and frequency of intensive glucose-lowering treatment and severe hypoglycemia among adults with type 2 diabetes mellitus?
Findings In this cohort study of 31 542 US adults with type 2 diabetes, of whom 12% had clinically complexity because of serious comorbidities and/or age of 75 years or older, 731 patients (18.7%) with high clinical complexity and 7317 patients (26.5%) with low clinical complexity received intensive glucose-lowering treatment. Intensive treatment of patients with high clinical complexity significantly increased the adjusted incidence of severe hypoglycemia from 1.7% to 3%.
Meaning Clinically complex and elderly patients with type 2 diabetes are frequently treated intensively, thereby increasing their risk of severe hypoglycemia.
We conducted a retrospective analysis of data from the OptumLabs Data Warehouse (OLDW), a deidentified administrative claims database of more than 100 million individuals enrolled in private and Medicare Advantage plans across the United States (eMethods 1 in the Supplement).26,27 There was no patient involvement in this study. Study data were accessed using techniques adherent to the Health Insurance Portability and Accountability Act of 1996, and because this study involved analysis of preexisting, deidentified data, the Mayo Clinic Institutional Review Board deemed it exempt from institutional review board approval.
We identified adults (≥18 years old) with stable, controlled type 2 diabetes from January 1, 2001, through December 31, 2011, who had 2 consecutive HbA1c tests that revealed levels less than 7.0% within a 24-month period (Figure 1 and eMethods 1 and eFigure 1 in the Supplement). Date of cohort entry was defined by the second (index) HbA1c test. As shown in Figure 1 and detailed in eMethods 2 in the Supplement, we first identified 5 297 670 patients within the OLDW who met the Healthcare Effectiveness Data and Information Set criteria28 for diabetes between 2001 and 2011. Patients with no HbA1c results or HbA1c levels of 7.0% and higher were excluded, leaving 619 231 individuals. Most patients were excluded on the basis of absent HbA1c because the OLDW includes laboratory results for a convenience sample based on data-sharing agreements between OptumLabs and commercial laboratories. To restrict the study population to patients with stable glycemic control, only 329 973 individuals with another HbA1c level less than 7.0% preceding the index HbA1c within 24 months were included.
We excluded 12 108 patients with severe hypoglycemia or hyperglycemia during the 12 months preceding the index HbA1c because they are at increased risk for recurrent hypoglycemia and likely not subject to usual care; 52 016 patients with type 1, gestational, nonclinical, and secondary diabetes because these conditions may have different treatment goals and natural histories; 10 134 patients with any insulin prescription during 120 days preceding the index date because insulin is a known risk factor for hypoglycemia and claims data do not allow for ascertainment of insulin dose and treatment intensity change; 214 033 patients with lack of continuous enrollment for 24 months; 8999 patients younger than 18 years; and 1141 patients with incomplete demographic or enrollment information.
Patients entered the cohort once, the first time they became eligible, and were followed for 24 months (up to 2013). They were stratified on the basis of index HbA1c measurements into 3 categories based on guideline recommendations for diabetes diagnosis and management: 5.6% or less, 5.7% to 6.4%, and 6.5% to 6.9%.14-20 Patients were censored on a severe hyperglycemic event because that may precipitate changes in therapy and confound analyses.
High vs low clinical complexity was defined based on the framework developed by the American Diabetes Association and the AGS21 as a composite measure of age of 75 years or older or high comorbidity burden defined by the presence of end-stage renal disease, dementia, or 3 or more serious chronic conditions (eMethods 3 in the Supplement).
Date of index HbA1c test (2001-2011) was recorded to account for secular trends in glycemic targets, treatment practices, and glucose-lowering medications and presented in 2-year increments except in 2011. Demographic variables included age, sex, race/ethnicity, and US Census region at the time of index HbA1c test. Specialties of health care professionals seen were measured for the 12-month period after the index HbA1c test because patients receiving specialty care may have different disease severity, comorbidity burden, health care use, and prescribed treatments than patients cared for by generalists. Endocrinologists, cardiologists, and nephrologists were chosen because they were the most commonly seen diabetes-related specialists in this population. Patients seen by multiple specialists were counted toward each specialty.
Baseline treatment regimens were identified from pharmacy claims within 120 days preceding the index HbA1c test date. Diabetes medications were grouped into 9 classes (eTable 1 in the Supplement); combination tablets were considered as belonging to both classes. Treatment changes were ascertained by comparing pharmacy claims 120 days after vs before the index HbA1c test date, which accounts for a health care professional’s review of HbA1c test results (30 days) and an additional 90 days for the preceding prescription to be completed until time for next medication fill.
Intensive treatment was defined based on the index HbA1c test and either treatment regimen at the time that HbA1c test was performed or treatment change after that HbA1c test result (eFigure 1 in the Supplement). For patients with an index HbA1c level of 5.6% or less, intensive treatment was defined as use of any medications on the index date or treatment initiation within 120 days of index date because this HbA1c level is below the threshold for treatment as recommended by clinical guidelines.14-20 For patients with an index HbA1c level of 5.7% to 6.4%, intensive treatment was defined as use of 2 or more drugs at the time of the index test (because the HbA1c level was also <7.0% before that test) or treatment intensification by addition of 1 or more new drugs or insulin after the index date (because these patients’ diabetes was already controlled per the guidelines).14-20 For patients with an index HbA1c level of 6.5% to 6.9%, intensive treatment was defined as the addition of 2 or more drugs or insulin after the index HbA1c test date (no baseline treatment criterion). The last definition is a conservative criterion that underestimates intensive treatment as defined by most professional societies that recommend targeting an HbA1c level of 7.0% rather than 6.5% and may view any treatment escalation at this point to be intensive treatment.15-20 None of the guidelines recommend the addition of 2 drugs for HbA1c levels of 6.5% to 6.9%.14-20
Treatment deintensification was defined by removing 1 or more drugs within 120 days after the index HbA1c test date. Treatment regimens that did not meet the criteria for intensive treatment were classified as standard treatment.
First episode of severe hypoglycemia during the 24 months after the index HbA1c test was identified by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), codes 251.x and 250.8 (Ginde algorithm)29 and 962.3 in the principal position of any (ambulatory, emergency department, or hospital) evaluation and management encounter.
To separate the incidence of hypoglycemia caused by sulfonylurea agents vs otherwise intensive treatment, we conducted a sensitivity analysis for the risk of hypoglycemia (observed and risk adjusted) after excluding 7601 patients receiving sulfonylurea or glinide drugs after the index HbA1c test date (eMethods 4 in the Supplement). Furthermore, because metformin may be used to treat prediabetes and other conditions, we conducted a second sensitivity analysis that excluded 5030 patients classified as receiving intensive treatment solely on the basis of metformin (eMethods 5 in the Supplement).
Data are presented as frequencies and means for all variables. Univariate between-group comparisons were performed using χ2 tests for categorical and binary variables and Kruskal-Wallis tests for continuous variables.
Multivariable logistic regression separately examined the risk-adjusted probabilities of intensive treatment and severe hypoglycemia. Adjustment variables were set to the sample means30 of sex, race (white, nonwhite, unknown), household income, US region, index HbA1c test date, and health care professional specialty.
Risk-adjusted probabilities and 95% CIs for intensive treatment were calculated for patients with low and high clinical complexity, adjusting for the aforementioned variables. The association between intensive treatment and severe hypoglycemia was examined in a second logistic regression model in which the main predictor was a 4-level measure of patient complexity and treatment intensity: (1) low complexity with standard treatment, (2) low complexity with intensive treatment, (3) high complexity with standard treatment, and (4) high complexity with intensive treatment. Adjustment variables were set to the sample means of index HbA1c level, medications used after testing, and the aforementioned variables. Analyses were conducted using SAS statistical software, version 9.3 (SAS Institute Inc), and STATA software, version 13.1 (StataCorp).
Baseline characteristics of the 31 542 patients included in the study stratified by clinical complexity are given in Table 1. Overall, the median age was 58.0 years, 15 483 (49.1%) were female, and 18 188 (57.7%) were white. The index HbA1c level was 5.6% or less in 3283 patients (10.4%), 5.7% to 6.4% in 18 014 patients (57.1%), and 6.5% to 6.9% in 10 245 patients (32.5%). At the time that the index HbA1c level was measured, 10 370 (32.9%) were not taking any glucose-lowering medications, 11 883 (37.7%) received 1 drug, 6710 (21.3%) received 2 drugs, and 2579 (8.2%) received 3 or more drugs. High clinical complexity was present in 3910 patients (12.4%) because of age of 75 years or older (n = 3048 [9.7%]), high burden of illness (n = 470 [1.5%]), or both (n = 392 [1.2%]). Patients with high clinical complexity were significantly more likely to be treated with lifestyle management or only 1 diabetes medication, and had higher index HbA1c levels, compared with patients with low clinical complexity who had greater prevalence of polypharmacy and lower index HbA1c levels (Table 1).
In total, 8048 patients (25.5%) were treated intensively, including 7317 patients (26.5%) with low clinical complexity and 731 patients (18.7%) with high clinical complexity (Table 2). Most patients met the criteria for intensive treatment based on their baseline treatment regimen (6033 patients [21.8%] with low clinical complexity and 620 patients [15.9%] with high clinical complexity); a smaller proportion had their treatment intensified despite low index HbA1c level (1592 patients [5.8%] with low clinical complexity and 139 patients [3.6%] with high clinical complexity). Importantly, 5053 intensively treated patients (76.0%) did not have their treatment deescalated after the low HbA1c test result was obtained, with 4571 patients (75.8%) with low clinical complexity and 482 patients (77.7%) with high clinical complexity continuing with their baseline intensive regimen.
The risk-adjusted probability of intensive treatment was 25.7% (95% CI, 25.1-26.2) for patients with low clinical complexity and 20.8% (95% CI, 19.4%-22.2%) for patients with high clinical complexity (absolute difference, 4.9%; 95% CI, 3.4%-6.4%; P < .001). This probability includes the higher risk-adjusted probability of intensive baseline regimen among patients with low vs high clinical complexity (21.0% [95% CI, 20.5%-21.5%] vs 17.3% [95% CI, 16.0%-18.6%]), as well as undergoing treatment intensification despite low index HbA1c levels (5.3% [95% CI, 5.1%-5.6%] vs 4.0% [95% CI, 3.3%-4.7%]) (Table 2).
Patients with high clinical complexity were significantly less likely to be treated intensively than patients with low clinical complexity (odds ratio [OR], 0.76; 95% CI, 0.69-0.83) (eFigure 2 in the Supplement). Women (OR, 0.84; 95% CI, 0.80-0.89) and nonwhite patients (OR, 0.91; 95% CI, 0.86-0.96) were also less likely to be treated intensively compared with men and white patients. Patients cared for by endocrinologists were more likely to be intensively treated (OR, 1.66; 95% CI, 1.53-1.79). Although the likelihood of intensive treatment was stable between 2001 and 2008, it decreased significantly after 2009 (OR, 0.71 [95% CI, 0.60-0.84] for 2009-2010, and OR, 0.64 [95% CI, 0.54-0.77] for 2011 compared with 2001-2002).
The overall unadjusted 2-year incidence of severe hypoglycemia was 1.4%, of which 326 cases (73.1%) were documented during ambulatory encounters, 82 (18.4%) resulted in emergency department visits, and 38 (8.5%) required hospital admission. Severe hypoglycemia was significantly more frequent among patients with high vs low complexity (112 [2.9%] vs 334 [1.2%]; P < .001). Among patients with low clinical complexity, the risk-adjusted probability of severe hypoglycemia did not increase with intensive treatment (1.02% [95% CI, 0.87-1.17] with standard treatment and 1.30% [95% CI, 0.98-1.62] with intensive treatment) (Figure 2). In contrast, among patients with high clinical complexity, the risk-adjusted probability of severe hypoglycemia increased significantly with intensive treatment from 1.74% (95% CI, 1.28%-2.20%) with standard treatment to 3.04% (95% CI, 1.91%-4.18%) with intensive treatment (absolute difference, 1.30%; 95% CI, 0.10%-2.50%).
The ORs of severe hypoglycemia were 1.72 (95% CI, 1.29-2.31) for high complexity with standard treatment vs low complexity with standard treatment groups, 3.05 (95% CI, 1.99-4.67) for high complexity with intensive treatment vs low complexity with standard treatment groups, and 1.77 (95% CI, 1.12-2.80) for high complexity with intensive treatment vs high complexity with standard treatment groups (Figure 3). Sulfonylurea and glinide therapy significantly raised the risk of severe hypoglycemia (OR, 2.19; 95% CI, 1.77-2.71). Patients treated by endocrinologists had significantly higher risk of hypoglycemia (OR, 1.65; 95% CI, 1.25-2.20), even after adjustment for the HbA1c level and medications used.
To determine whether our findings were driven by use of sulfonylureas, we performed sensitivity analyses excluding individuals using insulin secretagogues after the index HbA1c test date. All results remained consistent, although not always statistically significant given the smaller sample size (eResults 1, eTable 2, and eTable 3 in the Supplement). None of the study results were altered by excluding patients who were classified as intensively treated on the basis of metformin use or start only (eResults 2, eTable 4, and eTable 5 in the Supplement).
In this large national cohort of adults with controlled type 2 diabetes, more than a quarter of patients received intensive glucose-lowering therapy, including nearly 20% of patients with clinical complexity whose advanced age and comorbidities placed them at risk for treatment-related adverse events without substantial long-term benefit.12 Indeed, we found that even with standard glucose-lowering treatment, patients with high clinical complexity had almost double the rate of severe hypoglycemia compared with patients with low clinical complexity, and their risk of severe hypoglycemia was further nearly doubled by intensive treatment. Intensive treatment did not, however, significantly increase hypoglycemia risk among patients with low clinical complexity.
Recent guidelines, issued between 2010 and 2015, recommend initiation or escalation of pharmacotherapy for diabetes when the HbA1c level exceeds recommended targets (6.5% or 7.0%) in patients with low risk for hypoglycemia, low comorbidity burden, and life expectancy consistent with anticipated benefits of glycemic control.14-20 However, 1731 patients (5.5%) in our study, including 139 patients (3.6%) with high clinical complexity, began treatment or had their treatment intensified despite HbA1c levels much lower than these thresholds. Treatment deintensification is also an important aspect of individualized diabetes management, and clinical inertia encompasses not only failure to intensify therapy in response to elevated HbA1c levels31 but also failure to deescalate therapy in response to low HbA1c levels, particularly if treated with multiple glucose-lowering medications. In our study, 5053 patients (76.0%) receiving intensive treatment did not have their treatment deescalated, including 482 intensively treated patients (77.7%) with high clinical complexity. These data are similar to rates reported by Sussman and colleagues24 in the US Veterans Health Administration. Such failure to deescalate therapy in patients with very low HbA1c levels increases the risk of hypoglycemia, has no proven clinical benefit, exposes patients to potential adverse effects, and increases burden of treatment.32
Our study identified several factors associated with intensive treatment and hypoglycemia. Women and nonwhite patients were less likely to be treated intensively, which may reflect underlying disparities in diabetes care.33,34 Patients treated by endocrinologists and nephrologists were more likely to be treated intensively, consistent with prior studies35,36 and possibly attributable to greater emphasis on lowering HbA1c levels to reduce complications or a focus on treating diabetes without placing it in the context of multiple potentially competing diseases. Patients under endocrinology and nephrology care were also more likely to experience severe hypoglycemia even after treatment intensity and medical complexity were accounted for, warranting further investigation.
Furthermore, we examined the often concurrent effects of sulfonylurea use and intensive treatment on hypoglycemia. We were concerned to find significantly more sulfonylurea and glinide use among patients with high clinical complexity (6294 low complexity patients [22.8%] and 1307 high complexity patients [33.4%] were treated with either sulfonylurea or glinide after the index HbA1c test), despite the AGS strongly advising against sulfonylurea use by elderly individuals.37 As expected, sulfonylureas increased hypoglycemia risk irrespective of treatment intensity. However, we also found that patients with high clinical complexity had significantly higher rates of severe hypoglycemia even without sulfonylurea use, and intensive treatment that does not include sulfonylureas may further elevate hypoglycemia risk.
The rates of intensive treatment decreased during the study, particularly after 2009. This finding may be attributable to increasing uncertainty about long-term benefits of tight glycemic control4,38,39 and awareness of hypoglycemia risk posed by targeting HbA1c levels less than 6.5% to 7.0%.2,3 However, the association between intensive treatment and hypoglycemia remained unchanged over time, despite more prevalent use of novel glucose-lowering agents with lesser risk of hypoglycemia.36,40,41 Intensive treatment with any glucose-lowering drugs, even those not typically associated with hypoglycemia, should therefore be prescribed with caution, particularly to patients with high clinical complexity.
Our study has several important limitations, including stringent inclusion criteria that restricted the population to patients with type 2 diabetes who achieved and maintained glycemic control without use of insulin. Patients receiving insulin therapy at baseline were excluded because insulin may precipitate hypoglycemia for reasons beyond intensive treatment (eg, missed meals, illness, physical activity) and insulin dose changes cannot be reliably captured by pharmacy claim data. Because the study cohort was derived from a data set of privately insured and Medicare Advantage beneficiaries, the unadjusted rates of intensive treatment and severe hypoglycemia may not be directly generalizable to the broader US or international population. The association between intensive treatment and severe hypoglycemia, however, is likely comparable once pertinent covariates are accounted for. Another limitation stems from the fact that we considered treatment change that occurred within 120 days of the HbA1c test but measured rates of severe hypoglycemia during 2 years of follow-up, which may miss patients who received standard treatment at the time of cohort entry but were intensified later, causing hypoglycemia. Conversely, patients who were intensively treated at baseline and had treatment deintensified later may have avoided hypoglycemia, thereby decreasing the measured association between intensive treatment and severe hypoglycemia. Individuals who may have died during follow-up were excluded because of lack of continuous enrollment. Finally, not all hypoglycemic events culminate in a clinical encounter, which would underestimate the incidence of severe hypoglycemia, particularly among younger and healthier patients, because frail and elderly patients and those without readily available support are more likely to require medical attention for severe hypoglycemia.
Intensive glucose-lowering therapy is common, including among older adults and those with high a burden of comorbidity. Although young and relatively healthy patients may tolerate intensive treatment, it nearly doubles the risk of severe hypoglycemia among elderly patients and patients with clinical complexity, yet it has uncertain short- and long-term benefits in this population. Individualized assessment of clinical complexity, in addition to careful consideration of likely risks and benefits of intensive glucose-lowering therapy, is therefore an important part of patient-centered diabetes management.
Accepted for Publication: March 16, 2016.
Corresponding Author: Rozalina G. McCoy, MD, Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (email@example.com).
Published Online: June 6, 2016. doi:10.1001/jamainternmed.2016.2275.
Author Contributions: Drs McCoy and Shah had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: McCoy, Shah.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: McCoy.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Yao.
Obtained funding: Shah.
Administrative, technical, or material support: Shah.
Study supervision: Shah.
Conflict of Interest Disclosures: Dr Lipska reported receiving support from the National Institute on Aging as a Paul Beeson Career Development awardee and from the Centers of Medicare & Medicaid Services to develop and maintain publicly reported quality measures. Dr Ross reported receiving support through Yale University from Medtronic Inc and Johnson and Johnson to develop methods of clinical trial data sharing; from the Centers of Medicare & Medicaid Services to develop and maintain performance measures that are used for public reporting; from the Blue Cross-Blue Shield Association to better understand medical technology evidence generation; and from the US Food and Drug Administration to develop methods for postmarket surveillance of medical devices. No other disclosures were reported.
Funding/Support: This study was funded by grant R18HS18339 from the Agency for Healthcare Research and Quality (Dr Shah) and the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (Dr McCoy).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Create a personal account or sign in to: